TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22749917

Group type: EXPERIMENTAL
Intervention: High concentrations of IgA in patients with temporal lobe epilepsy (TLE)
Number of subjects: 856

Group type: COMPARATOR
Intervention: Low concentrations of IgA
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Current use of topiramate
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Use of lamotrigine, nitrazepam, oxcarbazepine, topiramate, and valproic acid
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: High concentrations of IgG
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Low concentrations of IgG
Number of subjects: 856
Study: 22029223

Group type: EXPERIMENTAL
Intervention: Test formulation of quetiapine fumarate 25 mg film-coated tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference formulation of quetiapine fumarate 25 mg film-coated tablet
Number of subjects: 30
Study: 19346160

Group type: EXPERIMENTAL
Intervention: Gaboxadol 5mg
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10mg
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15mg
Number of subjects: 742

Group type: COMPARATOR
Intervention: Zolpidem 10mg
Number of subjects: 742
Study: 17917907

Group type: EXPERIMENTAL
Intervention: 8-week exercise programme
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal daily activities (Control)
Number of subjects: 27
Study: 16293902

Group type: EXPERIMENTAL
Intervention: Eccentric exercise with 4 weeks interval (n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eccentric exercise with 8 weeks interval (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eccentric exercise with 12 weeks interval (n = 11)
Number of subjects: 30
Study: 12058781

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9887851

Group type: EXPERIMENTAL
Intervention: Transmural home care programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 116
Study: 9183985

Group type: EXPERIMENTAL
Intervention: SRT task with secondary tone counting task and repeating sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRT task with secondary tone counting task and non-repeating sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRT task with varying inter-stimulus intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRT task without secondary tone counting task and repeating sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRT task without secondary tone counting task and non-repeating sequences
Number of subjects: 0
Study: 2718829

Group type: EXPERIMENTAL
Intervention: Modified balanced-placebo design
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard balanced-placebo design
Number of subjects: 179
Study: 1149490

Group type: EXPERIMENTAL
Intervention: co-trimoxazole (480 mg trimethoprim and 2,400 mg sulphamethoxazole daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: tetracycline (2 g daily)
Number of subjects: 116
Study: 29885826

Group type: EXPERIMENTAL
Intervention: ACEF score low-risk (≤1.45)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: ACEF score intermediate-risk (>1.45 and ≤2.0)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: ACEF score high-risk (>2.0)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: ACEF score
Number of subjects: 1901
Study: 28177187

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (T+C)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (T+P)
Number of subjects: 138
Study: 26298786

Group type: EXPERIMENTAL
Intervention: JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: JZP-110
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23764991

Group type: EXPERIMENTAL
Intervention: Wide-field digital retinal imaging (WFDRI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Binocular indirect ophthalmoscopy (BIO)
Number of subjects: 58
Study: 20508536

Group type: EXPERIMENTAL
Intervention: High-protein recovery diet (1.4/0.7/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isocaloric control condition (2.1/0.1/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-protein condition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12
Study: 18444947

Group type: EXPERIMENTAL
Intervention: Heparin-coated autotransfusion system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-heparin-coated autotransfusion system
Number of subjects: 24
Study: 16804556

Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched oolong tea
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12906366

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg capsule in the evening)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10784307

Group type: EXPERIMENTAL
Intervention: PGI2 5 microg x ml(‐1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PGI2 10 microg x ml(‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (Control)
Number of subjects: 28
Study: 9038439

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (single dose 2 h before surgery)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (every 12 h for 2 days before surgery)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 1889841

Group type: EXPERIMENTAL
Intervention: Renin inhibitor Ro 42-5892 (0.3 mg/kg injected at 30 minutes, followed by infusion at 0.1 mg/kg/hr from 30 to 240 minutes)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ang II infusion (2 ng/kg/min from 0 to 60 minutes and 4 ng/kg/min from 60 to 120 minutes)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of Ang II and Ro 42-5892 (same doses as above)
Number of subjects: 6
Study: 6133645

Group type: EXPERIMENTAL
Intervention: Beta-blocking drugs (specific drugs not mentioned)
Number of subjects: 0
Study: 31712342

Group type: EXPERIMENTAL
Intervention: Protocol-based intervention for reducing the duration of invasive mechanical ventilation after an 8-week training period.
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control group (baseline data collection) before the training period.
Number of subjects: 10000
Study: 29417623

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 26729895

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-lenalidomide (MPR)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: cyclophosphamide-prednisone-lenalidomide (CPR)
Number of subjects: 662

Group type: COMPARATOR
Intervention: lenalidomide plus low-dose dexamethasone (Rd)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Triplet (MPR and CPR)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Doublet (Rd)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: MPR
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: CPR
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Rd
Number of subjects: 662
Study: 24697402

Group type: EXPERIMENTAL
Intervention: More appropriate prosthesis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Less appropriate prosthesis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Prosthetic ankle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sound ankle
Number of subjects: 28
Study: 22147365

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1886

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and water pipe smoking
Number of subjects: 1886

Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke exposure
Number of subjects: 1886

Group type: EXPERIMENTAL
Intervention: History of schistosomiasis
Number of subjects: 1886
Study: 20558918

Group type: EXPERIMENTAL
Intervention: Intravenous cephazolin (CEZ) at 2 g/day for 5 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Oral levofloxacin (LVFX) at 300 mg/day for 5 days
Number of subjects: 129
Study: 18028054

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol (CHX/T) varnish
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride (F) varnish
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (uncoated discs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol (CHX/T) varnish (non-immersed)
Number of subjects: 0
Study: 16200264

Group type: EXPERIMENTAL
Intervention: Rotablator
Number of subjects: 22

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 22
Study: 12377852

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 266

Group type: COMPARATOR
Intervention: Cefuroxime with or without erythromycin
Number of subjects: 266
Study: 9916954

Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nasogastric decompression
Number of subjects: 61
Study: 7561823

Group type: EXPERIMENTAL
Intervention: Active medication (anticholinergic agents)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurses' guesses
Number of subjects: 0
Study: 1973718

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4 g every 24 hours for 5 to 7 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g every 12 hours for 5 to 7 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g every 24 hours for 5 to 7 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Short-course treatment regimens (any of the above)
Number of subjects: 92
Study: 6112444

Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Corset
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Combination of treatments
Number of subjects: 322
Study: 31348316

Group type: EXPERIMENTAL
Intervention: Pit and fissure sealants
Number of subjects: 228

Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 228
Study: 29664873

Group type: EXPERIMENTAL
Intervention: De-escalation pathway
Number of subjects: 246
Study: 26577936

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 2% and chondroitin sulfate 2% (Arthrum HCS®)
Number of subjects: 112
Study: 24934429

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic movement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference group (no specific intervention mentioned)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All interventions (stretching, dynamic movement, reference)
Number of subjects: 30
Study: 22670550

Group type: EXPERIMENTAL
Intervention: 100% oxygen dive
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air dive
Number of subjects: 11
Study: 20153482

Group type: EXPERIMENTAL
Intervention: Real rTMS (1800 stimuli at just below active motor threshold intensity, 1Hz for four consecutive days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 10
Study: 17356507

Group type: EXPERIMENTAL
Intervention: mepivacaine + ropivacaine 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mepivacaine + ropivacaine 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: mepivacaine 1.5% (300 mg)
Number of subjects: 30
Study: 16356430

Group type: EXPERIMENTAL
Intervention: Initial L-thyroxine dose of 50 mug
Number of subjects: 31

Group type: COMPARATOR
Intervention: Initial L-thyroxine doses (50 mug, 37.5 mug)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Moderate congenital hypothyroidism
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Time to normalize thyroid function > 2 weeks
Number of subjects: 31
Study: 12190674

Group type: EXPERIMENTAL
Intervention: Live Lactobacillus plantarum 299 with oat fibre
Number of subjects: 45

Group type: COMPARATOR
Intervention: Heat-killed Lactobacillus plantarum 299 with oat fibre
Number of subjects: 45
Study: 9523807

Group type: EXPERIMENTAL
Intervention: BIS (bispectral index) and sevoflurane concentration
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 95% SEF (spectral edge frequency)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MPF (median power frequency)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sevoflurane concentration
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: EEG parameters
Number of subjects: 69
Study: 7648821

Group type: EXPERIMENTAL
Intervention: 1-h daytime urine specimen collection
Number of subjects: 922

Group type: COMPARATOR
Intervention: Timed overnight urine collection
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Urinary albumin excretion rate (UAE)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Urinary albumin creatinine ratio (UACR)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Urinary albumin concentration (UAC)
Number of subjects: 922
Study: 2652018

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 44
Study: 328880

Group type: EXPERIMENTAL
Intervention: Ketoprofen (150-300 mg daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ibuprofen (1200-2400 mg daily)
Number of subjects: 102
Study: 31712348

Group type: EXPERIMENTAL
Intervention: Intensive skin surveillance programme consisting of 3D total-body photography, sequential digital dermoscopy, and melanoma-risk stratification.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical care (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive skin surveillance programme
Number of subjects: 0
Study: 28206732

Group type: EXPERIMENTAL
Intervention: MPFF 1000-mg oral suspension once daily
Number of subjects: 1139

Group type: COMPARATOR
Intervention: MPFF 500-mg tablets twice daily
Number of subjects: 1139
Study: 25494972

Group type: EXPERIMENTAL
Intervention: Sodium-induced hyperhydration (SIH)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Glycerol-induced hyperhydration (GIH)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water-induced hyperhydration (WIH)
Number of subjects: 17
Study: 24063913

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2314
Study: 21702670

Group type: EXPERIMENTAL
Intervention: Two-step composite finishing/polishing disc system (Enhance Flex NST-EF)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Four-step composite finishing/polishing disc system (Sof-Lex-SL)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Four-step composite finishing/polishing disc system (Super-Snap-SS)
Number of subjects: 75
Study: 19336514

Group type: EXPERIMENTAL
Intervention: Inhaled GH
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subcutaneous GH (sc GH)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled GH and sc GH
Number of subjects: 22
Study: 16672024

Group type: EXPERIMENTAL
Intervention: Resorbable screws made of poly (D.L‐lactide) acid (PDLLA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Titanium screws
Number of subjects: 8
Study: 15475033

Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE) 4 ml
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE)
Number of subjects: 19
Study: 11533101

Group type: EXPERIMENTAL
Intervention: CD34-selected PBPCs
Number of subjects: 190

Group type: COMPARATOR
Intervention: Unselected PBPCs
Number of subjects: 190
Study: 11299622

Group type: EXPERIMENTAL
Intervention: PROLENE hernia system (PHS) double mesh grafts
Number of subjects: 10
Study: 8778709

Group type: EXPERIMENTAL
Intervention: Progressive exercise protocol on a treadmill
Number of subjects: 17
Study: 1839436

Group type: EXPERIMENTAL
Intervention: Amlodipine (once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril (twice daily)
Number of subjects: 0
Study: 6223583

Group type: EXPERIMENTAL
Intervention: SPG (20 mg twice a week or 40 mg once a week) in combination with tegafur
Number of subjects: 190

Group type: COMPARATOR
Intervention: Tegafur (control group)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: SPG (20 mg twice a week or 40 mg once a week)
Number of subjects: 190
Study: 31823475

Group type: EXPERIMENTAL
Intervention: Category A (sheath removed upon return to recovery without activated clotting time (ACT))
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Category C (ACT check 1‐h postheparin and sheath removed once ACT < 160)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Category B (ACT check 1‐h postheparin and sheath removed without knowing the ACT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no ACT measurement)
Number of subjects: 152
Study: 27918841

Group type: EXPERIMENTAL
Intervention: summerMAX treatment (5-week program targeting social skills, nonliteral language skills, face-emotion recognition, interest expansion)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: summerMAX treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 57
Study: 29602860

Group type: EXPERIMENTAL
Intervention: Therabite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wooden spatula
Number of subjects: 0
Study: 27765029

Group type: EXPERIMENTAL
Intervention: Intervention group (resident-directed intervention)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 25201615

Group type: EXPERIMENTAL
Intervention: Dynamic Lumbar Stabilization (DLS) exercises
Number of subjects: 44
Study: 22883186

Group type: EXPERIMENTAL
Intervention: Transradial coronary intervention (TRI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI)
Number of subjects: 360
Study: 19842002

Group type: EXPERIMENTAL
Intervention: Usual source of healthcare (USHC)
Number of subjects: 3899

Group type: COMPARATOR
Intervention: No usual source of healthcare (USHC)
Number of subjects: 3899
Study: 17444308

Group type: EXPERIMENTAL
Intervention: Morphine plus 0.25 mg/kg ketamine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 41
Study: 16042793

Group type: EXPERIMENTAL
Intervention: Educational intervention on malaria transmission and prevention
Number of subjects: 132

Group type: COMPARATOR
Intervention: No educational intervention (Control)
Number of subjects: 132
Study: 12411833

Group type: COMPARATOR
Intervention: Cerebral perfusion volume in controls
Number of subjects: 50

Group type: COMPARATOR
Intervention: Volume loss index (VLI) corrected for age and sex
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percentage uptake of HMPAO
Number of subjects: 50

Group type: COMPARATOR
Intervention: Repeatability coefficient for controls
Number of subjects: 50
Study: 9696475

Group type: EXPERIMENTAL
Intervention: Capsaicin treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 26
Study: 7671174

Group type: EXPERIMENTAL
Intervention: Collaborative cardiovascular clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canadian Cardiovascular Collaboration (CCC)
Number of subjects: 0
Study: 2782361

Group type: EXPERIMENTAL
Intervention: Hydration (5% dextrose in lactated Ringer's solution, intravenous bolus and continuous infusion)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bed rest alone (control group)
Number of subjects: 48
Study: 31173127

Group type: EXPERIMENTAL
Intervention: High NUF rate (>1.75 mL/kg/h)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Increase in NUF rate (every 0.5 mL/kg/h)
Number of subjects: 1434
Study: 28651403

Group type: EXPERIMENTAL
Intervention: Daily group
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Intermittent group
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Comparison between daily and intermittent groups
Number of subjects: 328
Study: 26218785

Group type: EXPERIMENTAL
Intervention: acu‐TENS group (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo acu‐TENS control group (n=25)
Number of subjects: 50
Study: 23714287

Group type: EXPERIMENTAL
Intervention: Comprehensive care and support from a case manager (UP group)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Comprehensive care and support from a case manager plus a technological toolkit (UP-TECH group)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Brochures regarding available services (Control group)
Number of subjects: 450
Study: 21617516

Group type: EXPERIMENTAL
Intervention: Gross prosections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-dimensional stereoscopic computer model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both resources (gross prosections and 3D models)
Number of subjects: 0
Study: 19148765

Group type: EXPERIMENTAL
Intervention: Cognitively oriented Behavioral Rehabilitation (CBR) and Qigong
Number of subjects: 136

Group type: COMPARATOR
Intervention: Qigong only
Number of subjects: 136
Study: 16297472

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, ketogenic diet (LCKD) with nutritional supplementation (including fish, borage and flaxseed oil)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, ketogenic diet (LCKD)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low-fat, reduced-calorie diet (LFD)
Number of subjects: 119
Study: 15317700

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (15 mg/kg) half an hour before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral prednisolone (0.5 mg/kg) for 2 weeks, tapered postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (Intravenous methylprednisolone and Oral prednisolone)
Number of subjects: 40
Study: 11287372

Group type: EXPERIMENTAL
Intervention: Tremor presence and severity in patients with multiple sclerosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tremor-related disability
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of tremor severity with clinical features
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comparison of patients with and without tremor
Number of subjects: 100
Study: 9071936

Group type: EXPERIMENTAL
Intervention: 15 g coarse bran
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 15 g inert plastic particles
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 7 g ispaghula
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control values
Number of subjects: 13